89
Approximate Time
to Conversion to
Sinus Rhythm
Primary Route(s)
of Elimination
Elimination
Half-Life Major Adverse Effects
8–12 h Liver metabolism
Biliary excretion
9–36 d Bradycardia
Hypotension
QT prolongation
Phlebitis
Torsades de pointes (TdP)
3–8 h Liver (70%)
Kidney (30%)
†
12–27 h Atrial flutter
AV block
Dizziness
Dyspnea
Exacerbation of HFrEF
Headache
Nausea
QT prolongation
Ventricular tachycardia
(VT)
Visual disturbances
30–90 min Liver 2–12 h Nonsustained VT
QT prolongation
TdP
30–60 min Liver (16–33%)
Kidney (50–65%)
‡
3–4 h
(parent)
7 h (NAPA)
Agranulocytosis
AV block
Exacerbation of HFrEF
Hypotension
Neutropenia
QT prolongation
Rash
rombocytopenia
TdP
3–8 h Liver 9 h Atrial flutter
AV block
Dizziness
Dyspnea
Exacerbation of HFrEF
Nausea
Taste disturbances
VT
Visual disturbances
†
Flecainide is available in an intravenous dosage form in Europe.
‡
% of a dose excreted unchanged in urine.
